A single enzyme inside liver cells drives the production of triglycerides that, in excess, fuel the inflammation and scarring ...

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes ...

Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH ...

Obesity and metabolic disease new drug corporations D&D Pharmatech said on the 27th that in the United States it met all key histological endpoints in phase 2 of its investigational new drug candidate ...

Dorothy Gale (played by OPA sixth grader Madelynn McIntyre) is readying to leave Oz after the events of “The Wizard of Oz” ...

Scientists at UC San Diego have unveiled a potentially game-changing treatment for MASH, a severe fatty liver disease ...

Resmetirom is the first approved therapy in the US specifically for MASH, earlier known as NASH—a progressive fatty liver ...

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver ...

Cash utilization is offset by two items received in the first quarter of 2026 – the €17.0 million (US$20.0 million) first commercial milestone recognized at the end of 2025 and collected in early 2026 ...

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB ...

Trial liver safety data from the 'ESSENCE' trial confirm semaglutide's favourable hepatic profile in patients with Metabolic Dysfunction-associated Steatohepatitis (MASH), addressing a critical concer ...